Renown orthopedic surgeon Javad Parvizi, M.D. has been named to the Board of Advisors of Molecular Surface Technologies (MST), a New Brunswick, New Jersey-based company focused on covalently bonding proprietary antimicrobial molecules to implant surfaces.
Javad Parvizi, M.D. Joins Molecular Surface Technologies Board
1 min read Premium comments
#javadparvizi#molecularsurfacetechnologies
Dr. Parvizi, an orthopedic total joint surgeon, is director of Orthopedic Research at the Rothman Orthopaedic Institute, James Edwards Chair at Thomas Jefferson University Hospital, and Founder of the Parvizi Surgical Institute.
MST’s CEO Marc Burel said, “Dr. Parvizi has been studying periprosthetic joint infections for decades, and, as a world expert, brings a wealth of both scientific and clinical experience to the development and commercialization of our antimicrobial surface technology. We are very excited having Dr. Parvizi on board with us.”
According to the company, “MST has developed a technology platform providing a novel approach to attack and significantly reduce the scourge of orthopedic and spinal surgical implant infections. MST’s technologies are based on covalently bonding molecules to implant surfaces to elicit antimicrobial functions, bioactivity, direct bone growth, and/or lubricious (slippery) surfaces.”
Zeroing in on the most exciting aspect of the technology to him, Dr. Parvizi commented to OTW: ”The proprietary and unique chemistry developed by MST allows for modification of the surface of implants that will render them anti-microbial. I have been involved with infection prevention research for over two decades and have seen numerous innovations. I am very excited with MST technology as it has gone beyond proof of concept and appears to be very effective in preventing biofouling and attachment of common pathogens to the surface of implant.”
Elaborating on his new role, Dr. Parvizi stated, “I will be charged with providing guidance to the company on how to proceed with the design or pre-clinical and clinical studies to further demonstrate the efficacy of the product. I will be involved in deciding which clinical product line to target as the entry to market and also provide assistance to the leadership of the company during their interactions with the regulatory agencies, orthopedic industry and scientific community.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.